Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Therapeutic Effect of Different Treatment Course With Inhaled Corticosteroids in Eosinophilic Bronchitis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02002715
Recruitment Status : Completed
First Posted : December 6, 2013
Last Update Posted : June 5, 2019
Sponsor:
Information provided by (Responsible Party):
Kefang Lai, The First Affiliated Hospital of Guangzhou Medical University

Brief Summary:

This study aims to observe the therapeutic effect of different treatment course with inhaled corticosteroids in eosinophilic bronchitis patients.

The investigators hypothesize:

  1. Cough score will be improved after treatment with longer treatment course with inhaled corticosteroids in EB patients.
  2. The sputum eosinophil percentage will be decreased and recovered to normal level (Eos%<2.5%) with longer treatment course with inhaled corticosteroids in EB patients.
  3. The rate of recurrence after treatment will be decrease with longer treatment course with inhaled corticosteroids in EB patients

Condition or disease Intervention/treatment Phase
Eosinophilic Bronchitis Drug: Inhaled budesonide Phase 4

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 106 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomised, Open-label, Parallel-group Study of Therapeutic Effect of Different Treatment Course With Inhaled Corticosteroids in Eosinophilic Bronchitis Patients
Actual Study Start Date : March 2008
Actual Primary Completion Date : May 2018
Actual Study Completion Date : May 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Budesonide

Arm Intervention/treatment
Active Comparator: Inhaled budesonide for 4 weeks
inhaled Budesonide 100µg , 2puff Q12h for 4 weeks
Drug: Inhaled budesonide
inhaled Budesonide 2puff Q12h,total 400µg/day for 4 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 8 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 16 weeks
Other Name: Budesonide Powder for Inhalation

Active Comparator: Inhaled budesonide for 8 weeks
inhaled Budesonide 100µg , 2puff Q12h for 8 weeks
Drug: Inhaled budesonide
inhaled Budesonide 2puff Q12h,total 400µg/day for 4 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 8 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 16 weeks
Other Name: Budesonide Powder for Inhalation

Active Comparator: Inhaled budesonide for 16 weeks
inhaled Budesonide 100µg , 2puff Q12h for 16 weeks
Drug: Inhaled budesonide
inhaled Budesonide 2puff Q12h,total 400µg/day for 4 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 8 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 16 weeks
Other Name: Budesonide Powder for Inhalation




Primary Outcome Measures :
  1. The primary outcome was the relapse rate of eosinophilic bronchitis in one year. [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. change in percentage of eosinophil in induced sputum from baseline to post-treatment [ Time Frame: week 0,week 4,week 8,week 16 ]
  2. change in Cough visual analogue scale (VAS) and Cough Symptom Score (CSS) from baseline to post-treatment [ Time Frame: week 0,week 4,week 8,week 16 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients who have a history of cough as sole or main symptom lasting more than 3 weeks.
  2. Patients whose chest x-ray outcome was normal or without any active focus.
  3. Patients who were diagnosed with the result of sputum eosinophil percentage (Eos%) over 2.5%, and the negative result in bronchial provocation test by methacholine inhalation challenge.
  4. Patients who was aged from 18 years old (≥ 18 years old ) to 75 years old (≤ 75 years old).

Exclusion Criteria:

  1. Patients who is a smoker or ex-smoker and has smoked within the previous year or has a cumulative smoking history >10 pack-years or equivalence.
  2. Patients with concomitance of GERC (gastroesophageal reflux-related chronic cough), chronic bronchitis , bronchiectasis, bronchial tuberculosis, ACEI induced cough, bronchogenic carcinoma, psychologic cough, pulmonary fibrosis, bronchus foreign body, microlithiasis, tracheobroncheopathia osteochondroplastica, mediastinal tumor, left ventricular dysfunction.
  3. Female subjects who are pregnant, breast-feeding or risk of becoming pregnant during the study.
  4. Subjects who are known or suspected to be hypersensitive to any component of the study medication or relief medications.
  5. Subjects who have received any therapy in the previous 4 weeks, e.g.corticosteroids ,antihistamines, leukotriene receptor antagonist in previous 4 weeks
  6. Subjects who are diagnosed with past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, haematological disease, neurological disease, endocrine disease or pulmonary disease. e.g.nasal-sinus infection, lower respiratory tract infection, chronic bronchitis, emphysema, bronchiectasis, cystic fibrosis or bronchopulmonary dysplasia.
  7. Subjects who demonstrate significant abnormality on biochemistry, hematology, ECG.

    -


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02002715


Locations
Layout table for location information
China, Guangdong
Guangzhou Institute of Respiratory Disease
Guangzhou, Guangdong, China, 520120
Sponsors and Collaborators
The First Affiliated Hospital of Guangzhou Medical University
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Kefang Lai, professor, The First Affiliated Hospital of Guangzhou Medical University
ClinicalTrials.gov Identifier: NCT02002715    
Other Study ID Numbers: cough001
First Posted: December 6, 2013    Key Record Dates
Last Update Posted: June 5, 2019
Last Verified: June 2019
Keywords provided by Kefang Lai, The First Affiliated Hospital of Guangzhou Medical University:
eosinophilic bronchitis
inhaled corticosteroids
therapeutic effect
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchitis
Acute Disease
Respiratory Tract Diseases
Pathologic Processes
Bronchial Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections
Disease Attributes
Budesonide
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists